By: Olivia Cook
- Bacopa monnieri, an adaptogenic herb, contains powerful compounds like bacosides and quercetin that promote cognitive function, improve memory and reduce oxidative stress and inflammation in the brain.
- It has shown promising results in addressing neurodevelopmental issues, such as ADHD and neurodegenerative diseases like Alzheimer’s and Parkinson’s diseases by improving brain health, learning abilities and emotional well-being.
- B. monnieri‘s anti-inflammatory, antioxidant and neuroprotective effects are linked to its bioactive compounds, including bacosides (A and B), alkaloids (e.g., brahmine, herpestine) and flavonoids (e.g., quercetin). Bacosides are the herb’s primary triterpenoid saponins, with bacosides A and B being well-studied and associated with improving dopamine levels, reducing inflammation and supporting cognitive processes like learning and memory retention.
- The herb is generally considered safe, with no major toxicity observed in studies, though mild gastrointestinal side effects have been reported. Standard doses range from 150 to 3,000 mg daily for humans.
- Despite promising results, additional well-conducted clinical trials with larger sample sizes are needed to understand better the optimal dosage, long-term effects and mechanisms of B. monnieri for treating neurodevelopmental and neurodegenerative disorders.
Bacopa monnieri, an adaptogenic herb used in traditional medicine, has recently garnered attention for its neuroprotective and cognitive-enhancing effects. In particular, the herb was the focus of a systematic review published in Antioxidants in March 2024.
The review focused on B. monnieri‘s unique phytochemical composition and its bioactive compounds like bacosides. These plant chemicals play a crucial role in alleviating biomarkers and symptoms associated with neurodevelopmental and neurological issues from prenatal stages to old age.




